NovaMedica: Mioreol

Main article: Alzheimer's disease

2022: Launch of a drug for the treatment of Alzheimer's disease

On April 19, 2022, the Russian pharmaceutical company NovaMedica (investment project Rusnano) announced that it had developed and registered a combined drug. It combines donepezil and memantine molecules, which are the backbone of dementia therapy in Alzheimer's disease. The drug is registered under the name Mioreol. This is the first such combination in the Russian market, as well as in the EAEU and Europe.

R&D laboratory of the Technological Center "NovoMedica Innotech"

Myoreol is NovaMedica's own development and is designed to treat patients with moderate to severe dementia in Alzheimer's disease. Its peculiarity lies in the combination in one dosage form of two molecules that complement each other's action. This contributes to increasing patient adherence to therapy and the effectiveness of treating a complex disease such as Alzheimer's disease. Myoreol is released in the form of tablets in four doses, which facilitates titration and introduction into therapy: the drug is taken in stages in increasing doses.

Mioreol is produced in Russia - at the facilities of the NovaMedica Innotech Technology Center (a 100% subsidiary of NovaMedica), which provides the possibility of uninterrupted deliveries and flexible production planning in response to the growing market demand. Mioreol will arrive at pharmacy shelves in the second half of April 2022. The drug will be dispensed by prescription.

Production facilities of NovoMedica Innotech Technological Center

"We are proud that the decision to invest Rusnano in the development of Russian pharmaceuticals has led to such striking achievements as the formation of the Russian base for pharmaceutical research and development and the creation of domestic medicines. This is a reliable basis for building a drug safety strategy for our country. It is important that innovative developments are becoming more accessible to Russian patients. In her work, NovaMedica still has a number of products for the treatment of diseases of the central nervous system. We believe in the company and are very happy about its success, " Olga Shpichko, Deputy Chairman of the Board of Directors of NovaMedica, Managing Director for Investment Activities of Rusnano Management Company

"The creation of drugs relevant to Russian health care is an important part of NovaMedica's strategy aimed at improving the drug supply of Russian patients. We are progressively developing our own R&D program, which includes a range of products at different stages of clinical research or registration. Our developments focus on the treatment of central nervous system diseases and include indications such as neuropathic pain , migraine, cognitive and sleep disorders, moderate and severe forms of dementia, etc. " Elena Litvinova, CEO of NovaMedica

Production facilities of NovoMedica Innotech Technological Center

"Because Alzheimer's disease is a multifactorial disease, the use of polymodal, multicomponent therapy provides concurrent effects on multiple stages of disease development. The practical value of this approach has been confirmed by numerous clinical studies conducted abroad with memantine and donepezil. Timely initiated dementia combination therapy in Alzheimer's disease shows convincing results in slowing the progression of cognitive deficits, and optimizing the dosing regimen makes the use of the combination drug easier and more convenient for patients, " Zakhar Leikin, Medical Director of NovaMedica

Alzheimer's disease is the most common cause of dementia - according to WHO, it accounts for 60-70% of all cases. This neurodegenerative disease is classified as incurable. There are about 50 million people with dementia worldwide, and almost 10 million new cases are detected annually. In Moscow, 4.5% of the population aged 60 years and older suffers from Alzheimer's disease, 40% of them with pronounced severe forms.